We have located links that may give you full text access.
Hypotensive action of OPC-1427, a new beta-adrenergic blocking agent in rats.
8-Acetonyloxy-5-[3-(2-(3,4-dimethoxyphenyl)-ethylamino)-2-hydroxypropoxyl]-3,4-dihydrocarbostyril (OPC-1427), is a newly synthesized cardioselective beta-adrenoceptor blocking agent and we examined the effects of this compound given intraperitoneally to consious Kyoto Wistar normotensive (WKR), spontaneous hypertensive (SHR) and DOCA-NCl hypertensive (DOCA rat) rats. The results were compared to findings with propranolol and practolol. OPC-1427 produced a significant hypotensive action in SHR and DOCA rats and this effect was less in WKR. With propranolol and practolol effective hypotensive effects were seen in WKR and DOCA rats but not in the SHR. The efficacy of the hypotensive action of these agents was propranolol greater than OPC-1427 = practolol in WKR, OPC-1427 greater than practolol in SHR, and OPC-1427 greater than practolol = propranolol in DOCA rats. Thus OPC-1427 appears to be a promising beta-adrenoceptor blocking agent which exerts a hypotensive state, as demonstrated in hypertensive rats.
Full text links
Related Resources
Trending Papers
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International Journal of Molecular Sciences 2024 May 2
Use of Intravenous Albumin: A Guideline from the International Collaboration for Transfusion Medicine Guidelines.Chest 2024 March 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app